The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively.

ABSTRACT:

Introduction

Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance the cytotoxic effect and targeting ability, while reducing the toxicity of antitumor drugs, an antibody drug conjugate (ADC) was developed to deliver small molecular cytotoxic payloads directly to tumor cells by binding to specific antibodies via linkers.

Method

By reviewing published literature and the current progress of ADCs, we aimed to summarize the basic characteristics, clinical progress, and challenges of ADCs to provide a reference for clinical practice and further research.

Results

ADC is a conjugate composed of three fundamental components, including monoclonal antibodies,

SUBMITTER: Li WQ 

PROVIDER: S-EPMC8290258 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature